Swedish Orphan Biovitrum AB (publ) (SOBI) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Swedish Orphan Biovitrum AB (publ) (SOBI) has a cash flow conversion efficiency ratio of 0.079x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr2.98 Billion) by net assets (Skr37.72 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Swedish Orphan Biovitrum AB (publ) - Cash Flow Conversion Efficiency Trend (2002–2025)
This chart illustrates how Swedish Orphan Biovitrum AB (publ)'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Swedish Orphan Biovitrum AB (publ) Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Swedish Orphan Biovitrum AB (publ) ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Bank of Baroda
NSE:BANKBARODA
|
-0.146x |
|
Banco de Credito e Inversiones
SN:BCI
|
0.064x |
|
AB Volvo (publ)
ST:VOLV-A
|
0.135x |
|
Nordson Corporation
NASDAQ:NDSN
|
0.067x |
|
W P Carey Inc
NYSE:WPC
|
0.037x |
|
Shenwan Hongyuan Group Co Ltd
SHE:000166
|
-0.034x |
|
Sands China Ltd
F:599A
|
0.373x |
|
Banco de Sabadell S.A
MC:SAB
|
0.018x |
Annual Cash Flow Conversion Efficiency for Swedish Orphan Biovitrum AB (publ) (2002–2025)
The table below shows the annual cash flow conversion efficiency of Swedish Orphan Biovitrum AB (publ) from 2002 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr37.72 Billion | Skr8.56 Billion | 0.227x | +23.82% |
| 2024-12-31 | Skr40.30 Billion | Skr7.39 Billion | 0.183x | +38.91% |
| 2023-12-31 | Skr33.87 Billion | Skr4.47 Billion | 0.132x | -24.95% |
| 2022-12-31 | Skr26.52 Billion | Skr4.67 Billion | 0.176x | -25.40% |
| 2021-12-31 | Skr23.20 Billion | Skr5.47 Billion | 0.236x | -8.64% |
| 2020-12-31 | Skr20.21 Billion | Skr5.21 Billion | 0.258x | +20.22% |
| 2019-12-31 | Skr16.93 Billion | Skr3.63 Billion | 0.215x | -7.17% |
| 2018-12-31 | Skr9.04 Billion | Skr2.09 Billion | 0.231x | +16.23% |
| 2017-12-31 | Skr6.70 Billion | Skr1.33 Billion | 0.199x | +210.66% |
| 2016-12-31 | Skr5.35 Billion | Skr342.86 Million | 0.064x | -40.80% |
| 2015-12-31 | Skr4.69 Billion | Skr507.20 Million | 0.108x | +109.27% |
| 2014-12-31 | Skr4.52 Billion | Skr233.77 Million | 0.052x | +32.97% |
| 2013-12-31 | Skr4.77 Billion | Skr185.39 Million | 0.039x | -53.62% |
| 2012-12-31 | Skr4.84 Billion | Skr405.47 Million | 0.084x | +304.14% |
| 2011-12-31 | Skr4.96 Billion | Skr102.93 Million | 0.021x | +141.86% |
| 2010-12-31 | Skr4.34 Billion | Skr-215.10 Million | -0.050x | -213.80% |
| 2009-12-31 | Skr1.35 Billion | Skr58.88 Million | 0.044x | +111.04% |
| 2008-12-31 | Skr1.28 Billion | Skr-506.49 Million | -0.394x | -2156.87% |
| 2007-12-31 | Skr1.45 Billion | Skr-25.37 Million | -0.017x | +72.56% |
| 2006-12-31 | Skr1.38 Billion | Skr-87.96 Million | -0.064x | -66.41% |
| 2005-12-31 | Skr1.71 Billion | Skr-65.32 Million | -0.038x | +62.02% |
| 2004-12-31 | Skr2.08 Billion | Skr-209.03 Million | -0.101x | -127.94% |
| 2003-12-31 | Skr2.10 Billion | Skr755.60 Million | 0.360x | +6368.45% |
| 2002-12-31 | Skr1.73 Billion | Skr9.62 Million | 0.006x | -- |
About Swedish Orphan Biovitrum AB (publ)
Swedish Orphan Biovitrum AB (publ), a biopharma company, provides medicines in the areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. The company operates through three segments: Haematology, Immunology, and Specialty Care. It offers Alprolix for haemophilia B; ALTUVOCT for the treatment and prophylaxis of bleeding in patients with… Read more